tiprankstipranks
Company Announcements

Bioxyne Limited Reports Strong Financial Recovery for 2024 Half-Year

Story Highlights
Bioxyne Limited Reports Strong Financial Recovery for 2024 Half-Year

The latest announcement is out from Bioxyne Limited ( (AU:BXN) ).

Bioxyne Limited has reported a significant financial turnaround for the half-year ending December 31, 2024, with revenues from continuing operations increasing by 171% compared to the previous year. The company achieved a net profit of $3.28 million, a substantial improvement from the previous year’s loss, largely due to a non-cash goodwill write-down in 2023. This financial recovery positions Bioxyne favorably within the biotechnology sector, potentially enhancing stakeholder confidence and market positioning.

More about Bioxyne Limited

Bioxyne Limited operates in the biotechnology industry, focusing on the development and commercialization of health and wellness products. The company is primarily involved in the production of probiotics and other related health supplements, targeting markets that emphasize health and immune support.

YTD Price Performance: -10.0%

Average Trading Volume: 2,946,358

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$55.33M

See more data about BXN stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App